Incyte's New Therapy Shows Signs Of 'Disease-Modifying' Potential In Rare Blood Cancer

Benzinga12-08 22:27

Incyte Corporation (NASDAQ:INCY) on Sunday revealed new clinical data from two Phase 1 studies of INCA033989 for mutCALR-expressing myeloproliferative neoplasms (MPNs) at the 2025 American Society of ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2589359079?lang=en_US&edition=fundamental","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/12/08/Konskie--Poland---December-08--2024-Incy.jpeg?optimize=medium&dpr=2&auto=webp&width=630","is_english":true,"pubTime":"2025-12-08 22:27","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2589359079","market":"sh","top_or_hot":-1,"title":"Incyte's New Therapy Shows Signs Of 'Disease-Modifying' Potential In Rare Blood Cancer","media":"Benzinga","content":"<div>\n<p>Incyte Corporation (NASDAQ:INCY) on Sunday revealed new clinical data from two Phase 1 studies of INCA033989 for mutCALR-expressing myeloproliferative neoplasms (MPNs) at the 2025 American Society of ...</p>\n\n<a href=\"https://www.benzinga.com/news/health-care/25/12/49256485/incytes-new-therapy-shows-signs-of-disease-modifying-potential-in-rare-blood-cancer\">Source Link</a>\n\n</div>\n","source":"benzinga_hot_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Incyte's New Therapy Shows Signs Of 'Disease-Modifying' Potential In Rare Blood Cancer</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIncyte's New Therapy Shows Signs Of 'Disease-Modifying' Potential In Rare Blood Cancer\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-12-08 22:27 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/news/health-care/25/12/49256485/incytes-new-therapy-shows-signs-of-disease-modifying-potential-in-rare-blood-cancer><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Incyte Corporation (NASDAQ:INCY) on Sunday revealed new clinical data from two Phase 1 studies of INCA033989 for mutCALR-expressing myeloproliferative neoplasms (MPNs) at the 2025 American Society of ...</p>\n\n<a href=\"https://www.benzinga.com/news/health-care/25/12/49256485/incytes-new-therapy-shows-signs-of-disease-modifying-potential-in-rare-blood-cancer\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4532","symbol_name":"文艺复兴科技持仓","start_time":0,"source_url":"https://www.benzinga.com/news/health-care/25/12/49256485/incytes-new-therapy-shows-signs-of-disease-modifying-potential-in-rare-blood-cancer","article_id":"2589359079","we_media_id":null,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/12/08/Konskie--Poland---December-08--2024-Incy.jpeg?optimize=medium&dpr=2&auto=webp&width=630"],"rights":{"source":"benzinga_hot_news","url":"https://www.benzinga.com/news/health-care/25/12/49256485/incytes-new-therapy-shows-signs-of-disease-modifying-potential-in-rare-blood-cancer","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2589359079","pubTimestamp":1765204020,"columns":[],"sourceInfo":{"source_id":"benzinga_hot_news","name":"Benzinga"},"weMediaInfo":null,"summary":"Incyte Corporation  on Sunday revealed new clinical data from two Phase 1 studies of INCA033989 for mutCALR-expressing myeloproliferative neoplasms  at the 2025 American Society of Hematology  Annual Meeting.The preliminary analysis  evaluated the safety and efficacy of INCA033989 in myelofibrosis  patients with as measured by spleen volume reduction ≥25%  and ≥35% , change in MPN-Symptom Assessment Form , total symptom score , anemia response and mutCALR variant allele frequency  reduction.Exploratory analyses from the clinical studies of INCA033989 demonstrate the potential for disease-modifying activity in MF patients with a CALR mutation, the company said in a press release.Also Read: FDA Expands Incyte’s Opzelura Approval To Treat Atopic Dermatitis In Children. In the monotherapy arms, patients treated with INCA033989 experienced rapid and robust spleen and anemia responses and symptom improvements.At Week 24, 41.7% of all evaluable patients achieved SVR25, and 33.3%  achieved SVR","collect":0,"end_time":0,"defaultTopTitle":"benzinga.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4532":"文艺复兴科技持仓","TSS":"Total System Services","BK4581":"高盛持仓","BK4561":"索罗斯持仓","BK4144":"石油与天然气的储存和运输","BK4139":"生物科技","BK4109":"特种化学制品","INCY":"因塞特医疗","BK4590":"PTP","BK4588":"碎股","LU2463526074.USD":"NORDEA 1 - GLOBAL CLIMATE ENGAGEMENT \"BP\" (USD) ACC","BK4550":"红杉资本持仓","BK4585":"ETF&股票定投概念","ET":"Energy Transfer LP","ASH":"Ashland"},"translate_title":"Incyte的新疗法在罕见血癌中显示出“改善疾病”潜力的迹象","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ET":1,"ASH":1,"TSS":1,"INCY":1.5},"content_text":"Incyte Corporation (NASDAQ:INCY) on Sunday revealed new clinical data from two Phase 1 studies of INCA033989 for mutCALR-expressing myeloproliferative neoplasms (MPNs) at the 2025 American Society of Hematology (ASH) Annual Meeting.\nThe preliminary analysis (data cut off September 25, 2025) evaluated the safety and efficacy of INCA033989 in myelofibrosis (MF) patients with as measured by spleen volume reduction ≥25% (SVR25) and ≥35% (SVR35), change in MPN-Symptom Assessment Form (SAF), total symptom score (TSS), anemia response and mutCALR variant allele frequency (VAF) reduction.\nExploratory analyses from the clinical studies of INCA033989 demonstrate the potential for disease-modifying activity in MF patients with a CALR mutation, the company said in a press release.\nAlso Read: FDA Expands Incyte’s Opzelura Approval To Treat Atopic Dermatitis In Children\nIn the monotherapy arms, patients treated with INCA033989 experienced rapid and robust spleen and anemia responses and symptom improvements.\nAt Week 24, 41.7% of all evaluable patients achieved SVR25, and 33.3% (12/36) achieved SVR35.\nAmong patients not previously treated with a JAK inhibitor, 71.4% (5/7) achieved SVR25, and 57.1% (4/7) achieved SVR35.\nAmong those resistant or intolerant to JAK inhibitor treatment, 34.5% (10/29) and 27.6% (8/29) achieved SVR25 and SVR35 at Week 24, respectively.\nAnemia response occurred in more than half (56%; 14/25) of evaluable anemic patients, with 40% (10/25) of patients achieving a major response with INCA033989 treatment.\nNearly all patients treated with INCA033989 (93.3%) experienced improved symptoms, with 60% (27/45) achieving a ≥50% reduction in TSS (TSS50) as best response. At Week 24, 39.4% (13/33) of patients achieved a TSS50.\nMost patients (89.4%; 42/47) with ≥1 post-baseline VAF measurement experienced a reduction in mutCALR VAF, and 10.6% (5/47) achieved a ≥25% best reduction in VAF.\nMost patients (76.5%) in the studies had co-occurring mutations. Of those, 40.5% of response-eligible patients achieved SVR35 or an anemia response. Single-cell analyses in MF patients with high clonal complexity showed consistent reductions in all CALR-mutant clones, regardless of the presence of co-occurring variants.\nIn the INCA033989 and ruxolitinib combination arms, most MF patients experienced spleen volume reductions and symptom improvements.\nAt Week 24, half (50%; 6/12) of all evaluable MF patients achieved SVR25, and 25% (3/12) achieved SVR35.\nAmong the 14 evaluable patients, 86% had stable anemia, and one patient with non-transfusion dependent anemia had a major anemia response.\nThe majority of patients (81.3%; 13/16) treated with INCA033989 in combination with ruxolitinib experienced symptom improvement, and 33.3% (3/9) achieved TSS50 at Week 24.\nINCA033989 was well-tolerated, both as a monotherapy and in combination with ruxolitinib\nIn addition to myelofibrosis (MF), INCA033989 is also being evaluated in Phase 1 studies for the treatment of patients with essential thrombocythemia (ET).\nThe company plans to initiate a registrational program evaluating INCA033989 for ET patients harboring a Type 1 or non-Type 1 CALR mutation who are resistant or intolerant to at least one cytoreductive therapy in 2026.\nINCY Price Action: Incyte shares were down 2.46% at $99.99 during premarket trading on Monday, according to Benzinga Pro data.\nRead Next:\nPhoto via Shutterstock","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2589359079","isCrawlerRequest":true}